Arcellx

Arcellx Stock-Based Compensation

Delisted

The Stock-Based Compensation (SBC) of Arcellx (ACLX) as of Nov 21, 2026 is 77.89 M USD. In the previous year, Stock-Based Compensation (SBC) was 61.09 M USD — a change of 27.51% (higher).

Stock-Based Compensation

77.89 MUSD

YoY

27.51%

Last updated:

Stock-Based Compensation (SBC) of Arcellx is 2025 77.89 M USD. Stock-Based Compensation (SBC) of Arcellx was 2024 61.09 M USD. It decreases by 27.51% higher compared to the previous year.

The Arcellx Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
66,000.00 USD
Jan 1, 2019
136,000.00 USD
Jan 1, 2020
1.05 M USD
Jan 1, 2021
6.75 M USD
Jan 1, 2022
21.54 M USD
Jan 1, 2023
41.79 M USD
Jan 1, 2024
61.09 M USD
Jan 1, 2025
77.89 M USD
The Arcellx Stock-Based Compensation history
YEARStock-Based CompensationYoY
77.89 MUSD+27.51%
61.09 MUSD+46.18%
41.79 MUSD+93.97%
21.54 MUSD+218.98%
6.75 MUSD+542.63%
1.05 MUSD+672.79%
136,000.00USD+106.06%
66,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Stock-Based Compensation (SBC) of Arcellx is 77.89 M USD in 2025.

Stock-Based Compensation (SBC) of Arcellx changed from 61.09 M USD to 77.89 M USD, representing a 27.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Arcellx since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Arcellx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Arcellx

All Key Metrics — Arcellx